Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Rhythm Pharmaceuticals (NASDAQ:RYTM), a $6.4 billion market cap biotech company with impressive gross profit margins of 89%, saw Chief Financial Officer Hunter C. Smith sell 28,088 shares of common stock on August 12 and 13, according to a Form 4 filing with the Securities and Exchange Commission. The sales, executed under a 10b5-1 trading plan, were priced between $96.00 and $96.6322, resulting in proceeds of approximately $2.7 million.
On the same dates, Smith exercised options to acquire 28,088 shares of Rhythm Pharmaceuticals common stock at a price of $6.88, for a total value of $193,245. Following these transactions, Smith directly owns 116,915 shares of the company.
In other recent news, Rhythm Pharmaceuticals reported its second-quarter 2025 earnings, which revealed a wider-than-expected loss per share of -$0.75, missing analyst forecasts of -$0.67. Despite this earnings miss, the company’s revenue reached $48.5 million, surpassing the anticipated $43.75 million, marking a 29% increase quarter-over-quarter. This strong revenue performance led to several analyst firms adjusting their price targets for the company. H.C. Wainwright raised its price target to $100 from $80, maintaining a Buy rating due to the robust quarterly results. TD Cowen also increased its price target to $110 from $85, citing the impressive revenue growth that exceeded expectations. Additionally, Citizens JMP boosted its price target to $135 from $130, maintaining a Market Outperform rating, and highlighted the ongoing demand for Imcivree and the company’s efforts to expand its pipeline. Rhythm Pharmaceuticals is on track to submit regulatory applications for setmelanotide for hypothalamic obesity in the U.S. and EU this quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.